Anuh Pharma (506260) Q2 24/25 earnings summary

Executive summary

• Q2 FY25 revenue reached Rs 169.35 Cr, up 20% sequentially, driven by high-margin products and regulatory market expansion.

• EBITDA for Q2 FY25 was Rs 20.27 Cr, a 42% increase quarter-over-quarter, reflecting operational efficiency.

• EPS improved to Rs 3.00 from Rs 1.90 in the previous quarter, highlighting enhanced profitability.

• Unaudited financial results for the quarter and half year ended 30th September 2024 were reviewed and approved by the Board on 8th November 2024.

• Statutory auditors conducted a limited review and found no material misstatements in the financial statements.

Financial highlights

• Q2 FY25 operating revenue was Rs 165.95 Cr, up 20.34% from Q1 FY25; H1 FY25 revenue was Rs 303.86 Cr, down 2.3% year-over-year.

• Q2 FY25 PAT was Rs 15.04 Cr, up 58.19% sequentially; H1 FY25 PAT was Rs 24.55 Cr, down 4.04% year-over-year.

• EBITDA for Q2 FY25 was Rs 20.27 Cr with a margin of 12.22%, up from 10.36% in Q1 FY25.

• EPS for Q2 FY25 was Rs 3.00, compared to Rs 1.90 in Q2 FY24.

• Total comprehensive income for H1 FY25 was Rs 24.42 Cr, up from Rs 18.13 Cr in H1 FY24.

Outlook and guidance

• Anticipates continued momentum in H2 FY25, driven by new product launches from R&D, including Dapagliflozin and Ticagrelor.

• Strategic focus on expanding into Japan, Vietnam, and South Korea, and increasing corticosteroid market share.

• Plans to reduce dependency on China by developing indigenous suppliers.

• Solar power investment underway to enhance sustainability.

• Previous period figures regrouped and reclassified as necessary to align with current period reporting.